Published in final edited form as:

Prev Med. 2019 June ; 123: 288–298. doi:10.1016/j.ypmed.2019.03.040.

Multisite HPV infections in the United States (NHANES 2003–2014): an overview and synthesis

Andrew F. Brouwer^{a,*}, Marisa C. Eisenberg^a, Thomas E. Carey^b, and Rafael Meza^a

^aDepartment of Epidemiology, University of Michigan, 1415 Washington Heights, Ann Arbor, MI 48109, United States

^bDepartment of Otolaryngology/Head & Neck Surgery, University of Michigan, 1500 E. Medical Center Dr., Ann Arbor, 48109, United States

Abstract

HPV is the most common sexually transmitted infection in the U.S., infecting both anogenital and oral sites. Nationally representative data are collected through the National Health and Nutrition Examination Survey (NHANES). However, changing designations of HPV genotypes as high or low risk and varying underlying populations as new results are reported have made direct comparison of results difficult. We reanalyzed HPV data from NHANES derived from self-collected cervicovaginal swabs (women ages 18–59, 2003–14), penile swabs (men ages 18–59, 2013–14), and oral rinses (men and women ages 18–69, 2009–14), using consistent populations and definitions across NHANES cycles. These data strengthen our understanding of age trends in HPV prevalence: cervicovaginal prevalence decreases with age, penile prevalence increases with age, and oral prevalence is bimodal but with an earlier first peak in women. There is strong evidence for reduced prevalence of vaccine genotypes (6, 11, 16, 18) in vaccinated men and women (ages 18–24) at both genital (RR 0.2 (0.1–0.3) in women and 0.7 (0.1–5.4) in men) and oral sites (RR 0.1 (0.0–1.3) in women; no infections detected in vaccinated men). A more complete picture of the burden of HPV in the U.S. is emerging, including evidence for reduced HPV genital and oral prevalence in vaccinated individuals.

Keywords

human papillomavirus; prevalence; multisite; concordant infection; NHANES; vaccine efficacy

*Corresponding author: brouweaf@umich.edu (Andrew F. Brouwer).

Author's contributions

AB, RM, ME designed the study. AB performed the data analyses and drafted the manuscript. AB, RM, ME, TC provided clinical and public health insight for analyzing the results and editing the manuscript. All authors read and approved the final manuscript.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Preprint submitted to Preventive Medicine

Competing interests

The authors declare that they have no competing interests.

Introduction

The human papillomavirus (HPV) is the causal agent for nearly every cervical cancer, 90% of anal cancers, 60% of cancers at certain oral sites, and 40% of penile, vaginal, and vulvar cancers [32]. The appreciation of HPV's role in cervical cancer, and the importance of genotypes 16 and 18 in particular, led to the surveillance of cervicovaginal HPV in women in the United States in the National Health and Nutrition Examination Survey (NHANES), beginning in the 2003–2004 survey [9, 15]. A growing appreciation for HPV's role in oral and male cancers [20, 32, 35] led to the introduction of oral HPV testing in both men and women in NHANES starting in 2009–10 [21]. Testing for penile HPV began in 2013–2014 [25, 18], which allows for a more complete assessment of the epidemiology of HPV at the U.S. population level. However, many previous prevalence estimates are not directly comparable because they use different subsamples of the data (different age ranges in particular) or different classifications of HPV genotypes as high-risk.

Although HPV is the most common sexually transmitted infection in the U.S. [57], not all genotypes rate the same level of concern. Indeed, many strains have very low oncogenic potential, are asymptomatic, and clear within a few years [30, 17, 46, 47, 22, 36]. Studies have tested for different sets of genotypes and have different classifications of high- vs. low-risk genotypes, further confusing the picture, making comparisons between studies difficult, and undermining our abilities to understand implications for future cancer burden. In Table 1, we compare HPV genotype designation and population of interest for previous NHANES analyses; this table is not an exhaustive list of all studies that have used HPV data from NHANES but rather those focused on reporting new prevalence data.

The heterogeneity in age-ranges and variability in high-risk genotype classification across these studies make it hard to directly compare results across the literature. In this study, we use the 2012 International Agency for Research on Cancer (IARC) classification of risk potential [4, 31] consistently across years and infection site. Group 1 genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) are known to have oncogenic potential, Group 2A genotypes (68) are probably oncogenic, and Group 2B genotypes (26, 30, 34, 53, 66, 67, 69, 70, 73, 82, 85, 97) are possibly oncogenic.

Although many analyses of HPV data in NHANES have focused on a single outcome of interest, there has been increasing interest in multisite concurrence (infection at both sites, possibly of different genotypes) and concordance (infection at both sites by at least one of the same genotype) of HPV infections at genital and oral sites, and previous analyses have begun to explore the epidemiology of HPV as an explicitly multisite infection [61, 5, 34, 7, 52, 59]. In this analysis, we update our multiyear, multisite overview of HPV data in NHANES [7]. We contextualize the recently reported penile HPV prevalence and concordance [25, 18, 44, 52] and recently-summarized cervicovaginal and oral prevalence [44] by placing them alongside data from the previous surveys. We synthesize and update all oral and genital HPV infection data in NHANES. In particular, we present genital and oral HPV prevalence for both men and women, stratified by age and race, and prevalence of Group 1 HPV genotypes. Concordant infections are identified when both oral and genital data are available. Prevalence by genotype among men and women with genital, oral, and

concordant infections are also reported. Finally, we consider the relative risk of an HPV infection at both genital and oral sites given vaccination for both men and women.

Methods

Data

NHANES is a series of cross-sectional surveys conducted by CDC's National Center for Health Statistics (NCHS) over two-year periods that include both physical examinations in a mobile examination center (MEC) and interviews (both in-home and audio-assisted in-MEC) of a representative sample of the non-institutionalized, civilian U.S. population [9]. The demographic and vaccination data used in this study are self-reported by participants. Study design, weighting, and collection of samples have been previously described [15, 26, 21]. The NHANES survey 2003–14 was approved by the NCHS Research Ethics Review Board (2003–04: protocol #98–12; 2005–10: protocol #2005–06; 2011–14: protocol #2011–17), and documented consent was obtained from all participants.

Self-collected cervicovaginal swabs were collected and typed for women ages 14–59 in six NHANES surveys (2003–14) for 37 genotypes, namely 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55 (a subtype of 44), 56, 58, 59, 61, 62, 64 (a subtype of 34), 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 82 subtype IS39, 83, 84, and 89 (formerly CP6108). Self-collected penile swabs were collected and typed for men ages 14–59 in 2013–2014 for the same genotypes. Oral rinses were administered to both men and women ages 14–69 in three surveys (2009–14) and tested for the same genotypes. All samples were genotyped using a polymerase chain reaction (PCR) assay. More detailed laboratory methods are provided by NHANES [9]. The numbers of individuals sampled by demographic group are reported in Table 2. Data on individuals under 18 is restricted by NCHS and is not included in this analysis.

Statistical analysis

Statistical analyses were performed in SAS (v. 9.4). Estimates were made using MEC survey weights [3]. All analyses are restricted to individuals who had valid oral and genital HPV results in survey cycles when both tests were administered. We consider four analyses: i) prevalence of any HPV and Group 1 genotypes at genital and oral sites stratified by sex, age, and race/ethnicity, ii) prevalence of concordant infections, i.e., at least one infection of the same genotype at both genital sites (cervicovaginal or penile) and oral sites, stratified by age and race/ethnicity, iii) genotype prevalence among men and women with genital, oral, and concordant infections, and iv) prevalence of all, Group 1, and vaccine genotypes at genital and oral sites of 18–24-year-old men and women stratified by vaccination status. Individuals reporting at least one dose of an HPV vaccine were considered to be vaccinated. Survey participants self-identified as Mexican American, Other Hispanic, Non-Hispanic White, Non-Hispanic Black, or Other Race - Including Multiracial (and, in 2011–14, Non-Hispanic Asian). We define All Hispanic participants as those identifying as either Mexican American or Other Hispanic, and, following NCHS recommendations, we censor cycles 2003–06 for this category [49]. Confidence intervals are all at level of significance $\alpha=0.05$ (i.e., 95%

confidence intervals). Statistical details for relative risk and comparison of population calculations are given in the supplement.

Results

Population prevalence over time

We present the weighted population-level prevalence for genital and oral HPV in Table 2. For oral HPV, we present both the prevalence in the 18–59 year old population (for comparison to the population who were tested for genital HPV) and in the 18–69 year old population. We also age-adjusted the 18–59 year old population for each cycle to the respective female and male populations in the 2010 census; we found very little difference between adjusted and unadjusted prevalences, indicating that changes in the age composition of the U.S. population have not skewed our understanding of prevalence trends.

Cervicovaginal and Penile HPV prevalence

Stacked bar graphs of genital prevalence in women by age and race are given in Figure 1 for surveys 2003–2014. There is a decrease in HPV cervicogenital prevalence by age. Black women have an almost uniformly higher prevalence than women of other races.

Stacked bar graphs of genital prevalence in men by age and race are given in Figure 2. Unlike in women, there appears to be a moderate increase in HPV prevalence with age, and black men are more likely than men of other races to have a genital HPV infection.

Oral HPV prevalence

Stacked bar graphs of oral prevalence in women by age and race are given in Figure 3. Oral HPV prevalence in women follows a slightly bimodal pattern, peaking around ages 25 and 55, and white women are less likely to have an oral infection than women of other races. The trend in concordant infections in women by age appears to follow the oral prevalence trend more closely than the genital prevalence trend (i.e., is bimodal rather than strictly decreasing).

Stacked bar graphs of oral prevalence in men by age and race are given in Figure 4. Oral HPV prevalence is no longer clearly bimodal and may instead largely increase with age, peaking around age 60. Black men are more likely to have an oral HPV infection. The concordance trend may also be bimodal, although the second peak around 55–59 might be a data artifact.

Genotypes

In Figure 5, we present genotype prevalence among men and women who have genital, oral, or concordant infections. E.g., 9.3% of women who had a genital HPV infection tested positive for HPV 16, while 11.2% of women with concordant infections tested positive for HPV 16 (whether or not HPV 16 was the concordant genotype). Data are aggregated 2009–14 for increased power (with the exception of men with genital or concordant infections, where we necessarily constrain to 2013–14). Nevertheless, many results, particularly for

those with concordant infections, have a standard error that exceeds 30% and should be treated with additional caution [51].

Among women, HPV 16 is the most common oncogenic genotype at all sites; low-risk types 62 and 84 are also common among all sites. Oncogenic genotypes 39, 51, and 52 are also common among genital infections. Genotypes 53, 54, 61 and 89 are more common among women with genital infections than oral infections; while genotype 44 (subtype 55) is more common among oral infections than genital infections. Genotypes 35, 39, 56, and 66 were rare among concordant infections despite moderate prevalence among both genital and oral infections, although this may be an artifact of the small sample size.

Among men, HPV 16 is a common oncogenic strain among penile infections, but so are 39, 51, and 59, as previously seen [25, 18]. Indeed, although HPV 16 is by far the most common oncogenic strain among men with oral infections, genotype 59 is the most common concordant oncogenic strain. HPV 62, 84 and 89 are common low-risk genital strains among men in this sample.

Vaccination

We compare the prevalence of HPV (all, Group 1, and vaccine genotypes) among vaccinated and unvaccinated men and women ages 18–24 at genital and oral sites (Table 3); vaccination status is self-reported. This analysis pools participants in the 2009–10, 2011–12, and 2013–14 cycles, except for male genital infection, which is only available in 2013–14.

There is little evidence of protection by vaccination against all genotypes or all Group 1 genotypes for either sex at either site, with the possible exception of oral infections by Group 1 in women. However, there is strong evidence of protection against the vaccine genotypes 6, 11, 16, and 18 for both men and women at both sites, with the possible exception of penile infections, for which the protective effect was less pronounced. The vaccination effect against oral and genital infections in women appears to be of similar strength. There were no oral infections among vaccinated men for any of the vaccine genotypes; as there was 1% prevalence among unvaccinated men, there is evidence of a protective effect, although the number of vaccinated men was relatively small.

Discussion

This analysis presents a multiyear, multisite population analysis of genital and oral HPV infection in the U.S., unifying and synthesizing previous results by using the same underlying population and same genotype classification. These consistently analyzed data give us an improved understanding of the demographic patterns of HPV at both sites for both sexes.

The studies profiled in Table 1 display a surprising amount of variation in the list of HPV genotypes considered to be high-risk, and the authors often do not indicate the reasoning behind their classifications. Many studies [20, 10, 34, 25, 59] have used the classification given by the International Agency for Research on Cancer (IARC) in 2003 [48], which classified genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82 as

carcinogenic and types 26, 53, and 66 as probably carcinogenic. A few early studies [15, 26] appear to have extrapolated high-risk status from the α -species genotype groupings. For example, HPV 70 is listed as high-risk in these studies because it is an $\alpha 7$ species, along with 18, 45, 39, and 59. IARC updated its classification in 2012 to designate Group 1 genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) as having known oncogenic potential, Group 2A genotypes (68) as being probably oncogenic, and Group 2B genotypes (26, 30, 34, 53, 66, 67, 69, 70, 73, 82, 85, 97) as being possibly oncogenic [31]. We use this classification in our studies. More recently, FDA-approved clinical HPV tests have come on the market, such as cobas[®] HPV test [54], which designates genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 as high risk (these are Group 1, Group 2A, and type 66). The confusion over the classification of 66 is likely due to its downgraded status in the latest IARC monograph [31]. More recent studies have adopted this classification [18, 52, 38]. While the IARC classification is the best-available science, consistency with clinical testing is also important. Ultimately, researchers need to be aware of these conflicting classifications and choose one or more ways of presenting their data to best facilitate the contextualization of their results. Fortunately, despite the inconsistencies in genotype risk classification across studies, the fundamental conclusions remain largely the same.

In contrast to cervicovaginal HPV prevalence in women, which peaks around age 20, penile HPV prevalence appears to continue to increase with age, which is consistent both with the pattern of oral prevalence and previously reported age-trends for serum antibodies [5]. However, future surveys will be needed to better understand the variability in the age-specific estimates (i.e., is the increase monotonic, or is there a second peak around age 50?). The bimodal oral prevalence in men noted by Gillison et al. [21] in the 2009–10 survey is now significantly less pronounced among the all-genotype data (Figure 4), although Group 1 genotypes are clearly bimodal. All-genotype oral prevalence now appears to increase with age and peak around age 55 (Figure 4). The data for women, on the other hand, are still consistent with a bimodal pattern that mimics that of cervicovaginal prevalence in the less-than-40 ages but has a second peak around 55–60 (Figure 3). A similar bimodal pattern has been observed for cervicovaginal infection in women in Latin America [28, 37, 45, 29]. It remains to be seen whether this oral bimodal pattern for women is a cohort effect (i.e., the older birth cohorts have a higher oral HPV prevalence [6]) or is a true age effect (possibly a result of a second sexual debut, loss of immunity, or reactivation of latent infections) [12]. To better understand these patterns, future work will need to better understand how age-specific sexual behaviors differ by race and by birth cohort. Since the 1940s, there has been an increase in sexual activity in young people, with lower ages of sexual debut, more sexual partners, and more lenient attitudes toward premarital sex [62, 39]. Condom use increased in the 1980s, in response to the HIV/AIDS epidemic and other factors, and reached a plateau in the 2000s [60, 2, 8, 1, 33]. Analysis from NHANES has suggested that partner acquisition rates increased up through the 1980s, driving HPV infection [55]. There is a complex interplay of factors here that requires continued analysis.

From previous multisite analyses [61, 5, 34, 52, 59], we know that oral and genital infections are in general poorly correlated and should be tested for separately. Indeed, an individual may have an infection at only one site, infections of different genotypes at genital and oral sites (concurrent infection), or infections of the same genotype (concordant infection).

Although testing for anal HPV infection has not been included in NHANES protocols, results from smaller studies (e.g., [27, 24, 50, 58]) similarly suggest important interactions between the anal and cervicovaginal/penile sites. In this synthesis, we see that oral-genital concordance in women is highest in the youngest age group 18–24, possibly suggesting a simultaneous first infection (Figure 3). It is also higher in the 45–55 age range, which may be consistent with the second-sexual debut hypothesis of the bimodal oral prevalence [21, 5]. These results are consistent with our previous analysis on the 2009–12 data [5]. In men, there is no clear age-related pattern of concordance (Figure 4); in their multivariate analysis, Patel et al., [52] also found no significant associations by age. As new data becomes available, age-specific patterns of concurrence and concordance should be revisited.

Most genital HPV infections are not concordant with an oral infection (for both men and women), though a larger fraction of oral infections are concordant with genital infections. Interestingly, there are no striking differences in the overall distribution of genotypes among those who have genital, oral, and concordant infections (Figure 5). Deviations from expected patterns based on overall prevalence could potentially indicate, for instance, differences by genotype in tropism (tissue specificity) or different transmission/autoinoculation pressure from one site versus the other. Given the small numbers of individuals, particularly for concordant infections, it would be premature to interpret the existing slight deviations from expected patterns. Additional data and sophisticated statistical techniques may provide additional insight in the future.

There is a subtle difference in populations when considering multisite vs. single site analyses, namely that, when considering multisite infection, we include only those people who tested conclusively (that is, positively or negatively, not inconclusively) for HPV at both sites, rather than at just one site. Hence, multisite analyses must use slightly restricted populations. This distinction should have little effect on prevalence estimates but can explain what at first glance might appear to be discrepancies between different authors' analyses. E.g. the prevalence of penile HPV in men ages 18–59 in 2013–2014 is given as 45.2% in Han et al. [25] while it is 45.3% in Patel et al. [52]; Han et al. considered all men who were tested conclusively for penile HPV (N=1868), while Patel considered those tested for both penile and oral HPV (N=1683). While the difference in this example is slight, it should be acknowledged for when comparing study results.

There are currently three prophylactic HPV vaccines with FDA approval: Gardasil (HPV types 6, 11, 16, and 18; approved in 2006 for young women, 2009 for young men), Cervarix (types 16 and 18; approved in 2009 for young women), and Gardasil 9 (types 6, 11, 16, 18, 31, 33, 45, 52, 58; approved in 2014 for young women and men) [16]. These vaccines target genotypes associated with genital warts (HPV 6 and 11) and those associated with carcinogenesis (HPV 16, 18, 31, 33, 45, 52, and 58). The decision to include HPV 31, 33, 45, 52, and 58 in Gardasil 9 was based on prevalence in cervical cancers [56] rather than population-level infection prevalence. In both men and women and at both genital and oral sites, Group 1 genotypes 39, 51, and 59, which are not in the nonavalent vaccine, are all as or more prevalent than the majority of Group 1 genotypes in the vaccine (Figure 5). These genotypes should be closely monitored both in the population and in incident HPV-related cancers as the new vaccine is adopted in the U.S. Because genotype-specific prevalence can

vary between populations, future work is needed to continue to address potential health disparities in high-risk populations, such as HIV-infected individuals or men who have sex with men (MSM).

The comparison of HPV prevalence between vaccinated and unvaccinated people presents evidence of vaccine effectiveness against the four vaccine genotypes 6, 11, 16, and 18 (future analyses will have to contend with the impact of added genotypes to the Gardasil 9 vaccine). We see evidence of reduction in prevalence for all of the sites, with the possible exception of genital sites for men (relative risks: 0.2 (cervicovaginal in women), 0.7 (genital in men), 0.1 (oral in women), 0 (no oral positives among vaccinated men)). We should be cautious with the differences in oral prevalence because, although the differences are statistically significant, the absolute prevalence of HPV 6, 11, 16, and 18 (1% in both unvaccinated men and women) is low and the relative standard errors are high. Several studies have found evidence of vaccine impact at the population level [41, 42, 18], and these results complement the work of Markowitz et al. [42] and Chaturvedi et al. [11], who found similar results for young people (for cervicovaginal infections and oral infections, respectively). There are a couple of plausible explanations for the less dramatic reduction for genital prevalence in vaccinated men. First, because the male genitals are an external tissue, it is possible that HPV infections of the male genitals do not lead to a strong immune response (i.e., are less immunogenic than infections at other sites) and are less impacted by serum antibodies—whether natural or vaccine derived. However, this explanation belies the reduction in genital warts, which are external lesions, in men in vaccine randomized control trials [23]. Second, the uptake of the vaccine may be primarily in men who were already sexually active, especially in this older-than-optimal age group of 18–24, who could have received the vaccine no earlier than age 15; these men may have already been infected, reducing the efficacy of the vaccine. The vaccinated population may also have a higher percentage of high-risk men given that vaccination among men overall is low [25] and reported high levels of willingness to vaccinate among high-risk groups when recommended by a physician [13, 19, 53]. This explanation could also be responsible for the greater than one risk ratios for men at the oral sites for any and Group 1 genotypes.

The strength of this study is the large, well-designed, nationally representative sample that allows for analysis at the US population level. The cross-sectional design with a battery of tests for each individual allows for analysis of multiple outcomes simultaneously, and, in particular, allows for assessment of genotype concordance between oral and genital sites. Because testing for HPV is relatively new and this is the debut of testing for penile HPV, we are limited somewhat in describing patterns and trends. Nevertheless, by synthesizing several cycles of data, we are able to add confidence and context to previous studies and ensure we use a consistent definition of high-risk infection across all cycles and outcomes.

Acknowledgements

This work was supported by NIH grant U01CA182915.

References

- [1]. Anderson John E., Warner Lee, and MacAluso Maurizio. Condom use among us adults at last sexual intercourse, 1996–2008: An update from national survey data. *Sexually Transmitted Diseases*, 38(10):919–921, 2011. [PubMed: 21934564]
- [2]. Bankole A Darroch JE, and Singh S. Determinants of trends in condom use in the United States, 1988–1995. *Family Planning Perspectives*, 31(6):264–71, 1999. [PubMed: 10614516]
- [3]. Botman SL, Moore TF, Moriarty CL, and Parsons VL. Design and Estimation for the National Health Interview, 1995–2004. *Vital Health Stat 2*, 130:1–31, 2000.
- [4]. Bouvard Véronique, Baan Robert, Straif Kurt, Grosse Yann, Secretan Béatrice, Ghissassi Fatiha El, Benbrahim-Tallaa Lamia, Guha Neela, Freeman Crystal, Galichet Laurent, and Coglianor Vincent. A review of human carcinogens–Part B: biological agents. *The Lancet Oncology*, 10(4): 321–322, 2009. [PubMed: 19350698]
- [5]. Brouwer Andrew F., Eisenberg Marisa C., Carey Thomas E., and Meza Rafael. Trends in HPV cervical and seroprevalence and associations between oral and genital infection and serum antibodies in NHANES 2003–2012. *BMC Infectious Diseases*, 15(1):575, 2015. [PubMed: 26689203]
- [6]. Brouwer Andrew F, Eisenberg Marisa C, and Meza Rafael. Case Studies of Gastric, Lung, and Oral Cancer Connect Etiologic Agent Prevalence to Cancer Incidence. *Cancer Research*, 78(12): 3386–3397, 2018. [PubMed: 29907681]
- [7]. Brouwer Andrew F., Meza Rafael, and Eisenberg Marisa C.. Transmission heterogeneity and autoinoculation in a multisite infection model of HPV. *Mathematical Biosciences*, 270:115–125, 2015. [PubMed: 26518265]
- [8]. Catania JA, Canchola J, Binson D, Dolcini MM, Paul JP, Fisher L, Choi KH, Pollack L, Chang J, Yarber WL, Heiman JR, and Coates T. National trends in condom use among at-risk heterosexuals in the united states. *Journal of acquired immune deficiency syndromes (1999)*, 27(2):176–82, 2001. [PubMed: 11404540]
- [9]. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey. <http://www.cdc.gov/nchs/nhanes.htm>. Accessed January 20, 2016, 2014.
- [10]. Chaturvedi Anil K., Graubard Barry I., Broutian Tatevik, Pickard Robert K L, Tong Zhen Yue, Xiao Weihong, Kahle Lisa, and Gillison Maura L.. NHANES 2009–2012 findings: Association of sexual behaviors with higher prevalence of oral oncogenic human papillomavirus infections in U.S. men. *Cancer Research*, 75(12):2468–2477, 2015. [PubMed: 25873485]
- [11]. Chaturvedi Anil K., Graubard Barry I., Broutian Tatevik, Pickard Robert K.L., Tong Zhen Yue, Xiao Weihong, Kahle Lisa, and Gillison Maura L.. Effect of prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the United States. *Journal of Clinical Oncology*, 36(3):262–267, 2018. [PubMed: 29182497]
- [12]. Chaturvedi Anil K, Graubard Barry I, Pickard Robert K L, Xiao Weihong, and Gillison Maura L. High-Risk Oral Human Papillomavirus Load in the US Population, National Health and Nutrition Examination Survey 2009–2010. *Journal of Infectious Diseases*, 210:441–447, 2014. [PubMed: 24625808]
- [13]. Colón-López Vivian, Del Toro-Mejías Lizbeth M., Ortiz Ana P., Tortolero-Luna Guillermo, and Palefsky Joel M.. HPV awareness and willingness to HPV vaccination among high-risk men attending an STI clinic in Puerto Rico. *Puerto Rico Health Sciences Journal*, 31(4):227–231, 2012. [PubMed: 23844472]
- [14]. Dunne Eileen F, Sternberg Maya, Markowitz Lauri E, McQuillan Geraldine, Swan David, Patel Sonya, and Unger Elizabeth R. Human papillomavirus (HPV) 6, 11, 16, and 18 prevalence among females in the United States- National Health And Nutrition Examination Survey, 2003–2006: opportunity to measure HPV vaccine impact? *Journal of Infectious Diseases*, 204(4):562–5, 2011. [PubMed: 21791658]
- [15]. Dunne Eileen F, Unger Elizabeth R, Sternberg Maya, McQuillan Geraldine, Swan David C, Patel Sonya S, and Markowitz Lauri E. Prevalence of HPV infection among females in the United States. *JAMA*, 297(8):813–9, 2007. [PubMed: 17327523]

- [16]. Food and Drug Administration. Human Papillomavirus Vaccine. <https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172678>. Accessed January 9, 2019, 2018.
- [17]. Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Désy M, and Rohan TE. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. *Journal of Infectious Diseases*, 180(5):1415–23, 1999. [PubMed: 10515798]
- [18]. Gargano Julia W., Unger Elizabeth R., Liu Gui, Steinau Martin, Meites Elissa, Dunne Eileen, and Markowitz Lauri E.. Prevalence of Genital Human Papillomavirus in Males, United States, 2013–2014. *The Journal of Infectious Diseases*, 215(Cdc):2013–2014, 2017.
- [19]. Gerend Mary A, Madkins Krystal, Phillips Gregory II, and Mustanski Brian. Predictors of Human Papillomavirus Vaccination Among Young Men Who Have Sex With Men. *Sexually Transmitted Diseases*, 43(3):185–191, 2016. [PubMed: 26859806]
- [20]. Gillison Maura L, Alemany Laia, Snijders Peter J F, Chaturvedi Anil, Steinberg Bettie M, Schwartz Steve, and Castellsagué Xavier. Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. *Vaccine*, 30 Suppl 5:F34–54, 2012. [PubMed: 23199965]
- [21]. Gillison Maura L, Broutian Tatevik, Pickard Robert K L, Tong Zhen-you, Xiao Weihong, Kahle Lisa, Graubard Barry I, and Chaturvedi Anil K. Prevalence of oral HPV infection in the United States, 2009–2010. *JAMA*, 307(7):693–703, 2012. [PubMed: 22282321]
- [22]. Giuliano Anna R, Lee Ji-Hyun, Fulp William, Villa Luisa L, Lazcano Eduardo, Papenfuss Mary R, Abrahamsen Martha, Salmeron Jorge, Anic Gabriella M, Rollison Dana E, and Smith Danelle. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. *Lancet*, 377(9769):932–40, 2011. [PubMed: 21367446]
- [23]. Giuliano Anna R., Palefsky Joel M., Goldstone Stephen, Moreira Edson D., Penny Mary E., Aranda Carlos, Vardas Eftyhia, Moi Harald, Jessen Heiko, Hillman Richard, Chang Yen-Hwa, Ferris Daron, Rouleau Danielle, Bryan Janine, Marshall J. Brooke, Vuocolo Scott, Barr Eliav, Radley David, Haupt Richard M., and Guris Dalya. Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males. *New England Journal of Medicine*, 364(5):401–411, 2011. [PubMed: 21288094]
- [24]. Goodman Marc T, Shvetsov Yuri B, McDuffie Katharine, Wilkens Lynne R, Zhu Xuemei, Thompson Pamela J, Ning Lily, Killeen Jeffrey, Kamemoto Lori, and Hernandez Brenda Y. Sequential acquisition of human papillomavirus (HPV) infection of the anus and cervix: the Hawaii HPV Cohort Study. *The Journal of Infectious Diseases*, 201(9):1331–9, 2010. [PubMed: 20307204]
- [25]. Han Jasmine J., Beltran Thomas H., Song John W., Klaric John, and Choi Y. Sammy. Prevalence of Genital Human Papillomavirus Infection and Human Papillomavirus Vaccination Rates Among US Adult Men. *JAMA Oncology*, 28307:1–7, 2017.
- [26]. Hariri Susan, Unger Elizabeth R, Sternberg Maya, Dunne Eileen F, Swan David, Patel Sonya, and Markowitz Lauri E. Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003–2006. *Journal of Infectious Diseases*, 204(4):566–73, 2011. [PubMed: 21791659]
- [27]. Hernandez Brenda Y., McDuffie Katharine, Zhu Xuemei, Wilkens Lynne R., Killeen Jeffrey, Kessel Bruce, Wakabayashi Mark T., Bertram Cathy C., Easa David, Ning Lily, Boyd Jamie, Sunoo Christian, Kamemoto Lori, and Goodman Marc T.. Anal human papillomavirus infection in women and its relationship with cervical infection. *Cancer Epidemiology, Biomarkers & Prevention*, 14(11 Pt 1):2550–6, 2005.
- [28]. Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, Balmaceda I, Greenberg MD, Alfaro M, Burk RD, Wacholder S, Plummer M, and Schiffman M. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. *J Natl Cancer Inst*, 92(6):464–474, 2000. [PubMed: 10716964]
- [29]. Herrero Rolando, Castle Philip E, Schiffman Mark, Bratti M Concepción, Hildesheim Allan, Morales Jorge, Alfaro Mario, Sherman Mark E, Wacholder Sholom, Chen Sabrina, Rodriguez Ana C, and Burk Robert D. Epidemiologic profile of type-specific human papillomavirus

- infection and cervical neoplasia in Guanacaste, Costa Rica. *Journal of Infectious Diseases*, 191(11):1796, 2005. [PubMed: 15871111]
- [30]. Ho GYF and Bierman R. Natural history of cervicovaginal papillomavirus infection in young women. *New England Journal of Medicine*, 338(7):423–428, 1998. [PubMed: 9459645]
- [31]. International Agency for Research on Cancer. Human Papillomaviruses. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, 100(B):255–296, 2012.
- [32]. Jemal Ahmedin, Simard Edgar P, Dorell Christina, Noone Anne-Michelle, Markowitz Lauri E, Kohler Betsy, Ehemann Christie, Saraiya Mona, Bandi Priti, Saslow Debbie, Cronin Kathleen A, Watson Meg, Schiffman Mark, Henley S Jane, Schymura Maria J, Anderson Robert N, Yankey David, and Edwards Brenda K. Annual Report to the Nation on the Status of Cancer, 1975–2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)-Associated Cancers and HPV Vaccination Coverage Levels. *Journal of the National Cancer Institute*, 105(3):175–201, 2013. [PubMed: 23297039]
- [33]. Kahn Laura, Lowry Richard, Eaton Danice, and Wechsler Howell. Trends in HIV-related risk behaviors among high school students—United States, 1991–2011. *Morbidity and Mortality Weekly Report*, 61(29):556–60, 2012. [PubMed: 22832937]
- [34]. Kedarisetty Suraj, Orosco Ryan K., Hecht Avram S., Chang David C., Weissbrod Philip A., and Coffey Charles S.. Concordant Oral and Vaginal Human Papillomavirus Infection in the United States. *JAMA Otolaryngology Head & Neck Surgery*, 8895:1–9, 2016.
- [35]. Kreimer Aimée R. Prospects for prevention of HPV-driven oropharynx cancer. *Oral Oncology*, 50(6):555–9, 2014. [PubMed: 23876626]
- [36]. Kreimer Aimée R, Pierce Campbell Christine M, Lin Hui-Yi, Fulp William, Papenfuss Mary R, Abraham-sen Martha, Hildesheim Allan, Villa Luisa L, Salmeron Jorge J, Lazcano-Ponce Eduardo, and Giuliano Anna R. Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. *Lancet*, 6736(13):1–11, 2013.
- [37]. Lazcano-Ponce E, Herrero R, Munoz N, Cruz A, Shah KV, Alonso P, Hernandez P, Salmeron J, and Hernandez M. Epidemiology of HPV infection among Mexican women with normal cervical cytology. *International Journal of Cancer*, 91(3):412–420, 2001. [PubMed: 11169968]
- [38]. Lewis Rayleen M., Markowitz Lauri E., Gargano Julia W., Steinau Martin, and Unger Elizabeth R.. Prevalence of Genital Human Papillomavirus among Sexually Experienced Males and Females Aged 14–59 Years, United States, 2013–2014. *Journal of Infectious Diseases*, 217(6): 869–877, 2018. [PubMed: 29294016]
- [39]. Liu Gui, Hariri Susan, Bradley Heather, Gottlieb Sami L, Leichter Jami S, and Markowitz Lauri E.. Trends and patterns of sexual behaviors among adolescents and adults aged 14 to 59 years, United States.. *Sexually Transmitted Diseases*, 42(1):20–26, 2015. [PubMed: 25504296]
- [40]. Liu Gui, Markowitz Lauri E., Hariri Susan, Panicker Gitika, and Unger Elizabeth R.. Seroprevalence of 9 human papillomavirus types in the United States, 2005–2006. *Journal of Infectious Diseases*, 213(2):191–198, 2016. [PubMed: 26320259]
- [41]. Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, and Unger ER. Reduction in Human Papillomavirus (HPV) Prevalence Among Young Women Following HPV Vaccine Introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. *Journal of Infectious Diseases*, 208(3):385–393, 6 2013. [PubMed: 23785124]
- [42]. Markowitz Lauri E, Liu Gui, Hariri Susan, Steinau Martin, Dunne Eileen F, and Unger Elizabeth R. Prevalence of HPV After Introduction of the Vaccination Program in the United States. *Pediatrics*, 137(3):1–9, 2016.
- [43]. Markowitz Lauri E, Sternberg Maya, Dunne Eileen F, McQuillan Geraldine, and Unger Elizabeth R. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003–2004. *The Journal of Infectious Diseases*, 200(7):1059–67, 2009. [PubMed: 19719390]
- [44]. McQuillan Geraldine, Kruszon-moran Deanna, Markowitz Lauri E, Unger Elizabeth R, and Paulose-ram Ryne. Prevalence of HPV in Adults Aged 1869: United States, 20112014. *NCHS Data Brief*, 280, 2017.
- [45]. Molano M, Posso H, Weiderpass E, van den Brule AJC, Ronderos M, Franceschi S, Meijer CJLM, Arslan A, and Munoz N. Prevalence and determinants of HPV infection among

- Colombian women with normal cytology. *British Journal of Cancer*, 87(3):324–33, 2002. [PubMed: 12177803]
- [46]. Molano M, van den Brule Adriaan, Plummer Martyn, Weiderpass Elisabete, Posso Hector, Arslan Annie, Meijer Chris J. L. M., Munoz Nubia, and Franceschi Silvia. Determinants of Clearance of Human Papillomavirus Infections in Colombian Women with Normal Cytology: A Population-based, 5-Year Follow-up Study. *American Journal of Epidemiology*, 158(5):486–494, 2003. [PubMed: 12936904]
- [47]. Moscicki Anna-Barbara, Schiffman Mark, Burchell Ann, Albero Ginesa, Giuliano Anna R, Goodman Marc T, Kjaer Susanne K, and Palefsky Joel. Updating the natural history of human papillomavirus and anogenital cancers. *Vaccine*, 30 Suppl 5:F24–33, 2012. [PubMed: 23199964]
- [48]. Munoz Nubia, Bosch F Xavier, de Sanjosé Silvia, Herrero Rolando, Castellsagué Xavier, Shah Keerti V, Snijders Peter J F, and Meijer Chris J L M. Epidemiologic classification of human papillomavirus types associated with cervical cancer. *The New England Journal of Medicine*, 348(6):518–27, 2003. [PubMed: 12571259]
- [49]. National Center for Health Statistics. National Health and Nutrition Examination Survey: Analytic guidelines, 1999–2010. *Vital Health Statistics*, 2(161), 2013.
- [50]. Nunes Emily M., Lopez Rossana V.M., Sudenga Staci L., Gheit Tarik, Tommasino Massimo, Baggio Maria L., Ferreira Silvaneide, Galan Lenice, Silva Roberto C., Lazcano-Ponce Eduardo, Giuliano Anna R., Villa Luisa L., and Sichero Laura. Concordance of Beta-papillomavirus across anogenital and oral anatomic sites of men: The HIM Study. *Virology*, 510(July):55–59, 2017. [PubMed: 28708973]
- [51]. Parker JD, Talih M, Malec DJ, Beresovsky V, Carroll M, Gonzales JF, Hamilton BE, Ingram DD, Kochanek K, McCarty F, Moriarty C, Shimizu I, Strashny A, and Ward B. National Center for Health Statistics Data Presentation Standards for Proportions. Technical Report 175, National Center for Health Statistics, 2017.
- [52]. Patel Eshan U., Rositch Anne F., Gravitt Patti E., and Tobian Aaron A. R.. Concordance of Penile and Oral Human Papillomavirus Infections Among Men in the United States. *The Journal of Infectious Diseases*, 215(8):1207–1211, 2017. [PubMed: 28329127]
- [53]. Reiter Paul L and McRee Annie-Laurie. HPV infection among a population-based sample of sexual minority women from USA. *Sexually Transmitted Infections*, pages 1–7, 2016.
- [54]. Roche Molecular Systems, Inc. cobas HPV Test. <https://www.accessdata.fda.gov/cdrhdocs/pdf10/p100020s017c.pdf>. Accessed January 9, 2019, 2015.
- [55]. Ryser Marc D., Rositch Anne, and Gravitt Patti E.. Modeling of US human papillomavirus (HPV) seroprevalence by age and sexual behavior indicates an increasing trend of HPV infection following the sexual revolution. *Journal of Infectious Diseases*, 216(5):604–611, 2017. [PubMed: 28931221]
- [56]. Saraiya Mona, Unger Elizabeth R., Thompson Trevor D., Lynch Charles F., Hernandez Brenda Y., Lyu Christopher W., Steinau Martin, Watson Meg, Wilkinson Edward J., Hopenhayn Claudia, Copeland Glenn, Cozen Wendy, Peters Edward S., Huang Youjie, Saber Maria Sibug, Altekruse Sean, and Goodman Marc T.. US assessment of HPV Types in cancers: Implications for current and 9-valent HPV vaccines. *Journal of the National Cancer Institute*, 107(6), 2015.
- [57]. Satterwhite Catherine Lindsey, Torrone Elizabeth, Meites Elissa, Dunne Eileen F, Mahajan Reena, Cheryl Banez Ocfemia M, Su John, Xu Fujie, and Weinstock Hillard. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. *Sexually Transmitted Diseases*, 40(3):187–93, 2013. [PubMed: 23403598]
- [58]. Smelov Vitaly, Muwonge Richard, Sokolova Olga, McKay-Chopin Sandrine, Eklund Carina, Komyakov Boris, and Gheit Tarik. Beta and gamma human papillomaviruses in anal and genital sites among men: Prevalence and determinants. *Scientific Reports*, 8(1):1–10, 2018. [PubMed: 29311619]
- [59]. Sonawane Kalyani, Suk Ryan, Chiao Elizabeth Y., Chhatwal Jagpreet, Qiu Peihua, Wilkin Timothy, Nyi-tray Alan G., Sikora Andrew G., and Deshmukh Ashish A.. Oral human papillomavirus infection: Differences in prevalence between sexes and concordance with genital human papillomavirus infection, NHANES 2011 to 2014. *Annals of Internal Medicine*, 167(10): 714–724, 2017. [PubMed: 29049523]

- [60]. Sonenstein Freya L., Pleck Joseph H., and Ku Leighton C.. Sexual activity, condom use and AIDS awareness among adolescent males. *Family Planning Perspectives*, 21(4):152–158, 1989. [PubMed: 2792332]
- [61]. Steinau Martin, Hariri Susan, Gillison Maura L, Broutian Tatevic R, Dunne Eileen F, Tong Zhenyue, Markowitz Lauri E, and Unger Elizabeth R. Prevalence of cervical and oral human papillomavirus infections among US women. *Journal of Infectious Diseases*, 209(11):1739–43, 2014. [PubMed: 24319284]
- [62]. Wells Brooke E. and Twenge Jean M.. Changes in young people’s sexual behavior and attitudes, 1943–1999: A cross-temporal meta-analysis. *Review of General Psychology*, 9(3):249–261, 2005.

Highlights:

- We revisit past analyses with consistent HPV genotype risk classification definitions
- Synthesizing data across survey years enhances our understanding of HPV epidemiology
- HPV infection at oral and genital sites is strongly age dependent
- A small but significant fraction of people have oral-genital concordant infections
- Effectiveness of HPV vaccine is seen at both oral and genital sites

Figure 1: Cervicovaginal HPV prevalence in women ages 18–59 by genotype group and concordance, stratified by age and race.

Stratification of cervicovaginal HPV prevalence in the U.S. by oncogenic potential (Group 1 genotypes are known to cause cancer) in the upper panels is given by age and race, where each bar represents survey cycles 2003–04, 2005–06, 2007–08, 2009–10, 2011–12, and 2013–14, respectively. Stratification by concordance (lower panels) is done similarly (concordant infections are defined as at least one simultaneous oral and genital infection of the same genotype). The points with error bars (95% CIs) give the average of the indicated outcome for the 2009–2014 data. The constraint to this time period allows comparison to oral outcomes.

Figure 2: Penile HPV prevalence in men ages 18–59 by genotype group and concordance, stratified by age and race.

Stratification of penile HPV prevalence in the U.S. by oncogenic potential (Group 1 genotypes are known to cause cancer) in the upper panels is given by age and race, where each bar is survey cycle 2013–14. Stratification by concordance (lower panels) is done similarly (concordant infections are defined as at least one simultaneous oral and genital infection of the same genotype). Because there is only one survey with penile outcomes, the error bars (95% CIs) are for this year only.

Figure 3: Oral HPV prevalence in women ages 18–69 by genotype group and concordance, stratified by age and race.

Stratification of oral HPV prevalence in women in the U.S. by oncogenic potential (Group 1 genotypes are known to cause cancer) in the upper panels is given by age and race (ages 18–59 only), where each bar represents survey cycles 2009–10, 2011–12, and 2013–14, respectively. Stratification by concordance (lower panels) is done similarly (concordant infections are defined as at least one simultaneous oral and genital infection of the same genotype). The points with error bars (95% CIs) give the 2009–14 average of the indicated outcome.

Figure 4: Oral HPV prevalence in men ages 18–69 by genotype group and concordance, stratified by age and race.

Stratification of HPV prevalence in men in the U.S. by oncogenic potential (Group 1 genotypes are known to cause cancer) in the upper panels is given for by age and race (ages 18–59 only), where each bar represents survey cycles 2009–10, 2011–12, and 2013–14, respectively. Stratification by concordance (lower panels) is done similarly (concordant infections are defined as at least one simultaneous oral and genital infection of the same genotype). The points with error bars (95% CIs) give the 2009–14 average of the indicated

outcome. Because penile outcomes are only available for 2013–14, the trend and error bars for penile–oral concordance are only for this survey.

Figure 5: Genotype prevalence among women and with genital, oral, or concordant HPV infections.

Genotype prevalence in U.S. is the 2009–14 average in each case but (f), where it is 2013–14. Each subcaption gives the number of people with the given type of infection and what (weighted) percentage of the population that number represents. Genotypes are color coded by oncogenic potential: Group 1 is oncogenic, Group 2 is possibly oncogenic, and all other are low-risk.

Table 1:
Previous analyses of HPV outcomes in NHANES.

Previous analyses have considered different underlying populations and different classifications of HPV genotypes. Note that genotypes 55, 64, and IS39 are now classified as subtypes of 44, 34, and 82, respectively. All studies used data from the full 37 genotype assay except where denoted by *, indicating only a subset of genotypes were considered.

Reference	Outcome	Age range	High-risk (HR) genotypes	Low-risk (LR) genotypes
Dunne [15]	Cervicovaginal prevalence 2003–04	14–59	16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 69, 70, 73, 82, 85, 82 [IS39]	6, 11, 32, 40, 42, 44, 54, 55, 61, 62, 64, 71, 72, 74, 81, 83, 84, 87, 89, 91
Markowitz [43]	Seroprevalence 2003–04*	14–59	16, 18	6, 11
Dunne [14]	Cervicovaginal prevalence 2003–06*	14–59	16, 18	6, 11
Hariri [26]	Cervicovaginal prevalence 2003–06	14–59	16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 64, 66, 67, 68, 69, 70, 73, 82, 82 [IS39]	6, 11, 40, 42, 54, 55, 61, 62, 71, 72, 81, 83, 84, 89
Gillison [21]	Oral prevalence 2009–10	14–69	16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82	6, 11, 40, 42, 54, 55, 61, 62, 64, 67, 69, 70, 71, 72, 81, 82 [IS39], 83, 84, 89
Markowitz [41]	Cervicovaginal prevalence 2003–10*	14–59	16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68	6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 67, 69, 70, 71, 72, 73, 81, 82, 82 [IS39], 83, 84, 89
Steinau [61]	Cervicovaginal–oral prevalence 2009–10	18–59	16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 64, 66, 68	6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 67, 69, 70, 71, 72, 73, 81, 82, 83, 84, 82 [IS39], 89
Chaturvedi [10]	Oral prevalence 2009–12	14–69	16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82	6, 11, 40, 42, 54, 55, 61, 62, 64, 67, 69, 70, 71, 72, 81, 82 [IS39], 83, 84, 89
Liu [40]	Seroprevalence 2005–06*	14–59	16, 18, 31, 33, 45, 52, 58	6, 11
Brouwer [5]	Cervicovaginal, oral, seroprevalence 2003–12	14–59/69	16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59	6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 82 [IS39], 83, 84, 89
Kedarisetty [34]	Cervicovaginal–oral concordance 2009–12	18–69	16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82	6, 11, 40, 42, 54, 55, 61, 62, 64, 67, 69, 70, 71, 72, 81, 83, 84, 89, 82 [IS39]
Markowitz [42]	Cervicovaginal prevalence 2003–12	14–34	16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68	6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 67, 69, 70, 71, 72, 73, 81, 82, 82 [IS39], 83, 84, 89
Han [25]	Penile prevalence 2013–14	18–59	16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82	6, 11, 40, 42, 54, 55, 61, 62, 64, 67, 69, 70, 71, 72, 81, 82 [IS39], 83, 84, 89
Gargano [18]	Penile prevalence 2013–14	14–59	16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68	6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 67, 69, 70, 71, 72, 73, 81, 82, 82 [IS39], 83, 84, 89
Patel [52]	Penile–oral concordance 2013–14	18–59	—	—
McQuillan [44]	Genital, oral prevalence 2013–2014	18–59/69	16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68	6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 67, 69, 70, 71, 72, 73, 81, 82, 82 [IS39], 83, 84, 89

Reference	Outcome	Age range	High-risk (HR) genotypes	Low-risk (LR) genotypes
Sonawane [59]	Oral prevalence, oral–genital concordance 2011–2014	18–59/69	16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82	6, 11, 40, 42, 54, 55, 61, 62, 64, 67, 69, 70, 71, 72, 81, 82 [IS39], 83, 84, 89
Lewis [38]	Cervicovaginal and penile prevalence in the sexually experienced, 2013–14	14–59	16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68	6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 67, 69, 70, 71, 72, 73, 81, 82, 83, 84, IS39, 89

Table 2:
Numbers of tested participants and prevalence.

Numbers of people (ages 18+) conclusively tested (had a positive or negative result) for HPV at genital and oral sites in the 2003–14 National Health and Nutrition Examination Surveys (NHANES) in the U.S. and weighted prevalence and prevalence age-adjusted to the 2010 U.S. population. Here, positive for HPV means that and individuals is positive for at least one of the 37 genotypes tested.

	Genital						Oral						
	Women			Men			Women		Men				
	03–04	05–06	07–08	09–10	11–12	13–14	13–14	09–10	11–12	13–14	09–10	11–12	13–14
All	1558	1728	1783	1955	1767	1985	1757	2461	2195	2446	2385	2215	2278
Mexican American	328	409	370	408	190	301	255	504	236	360	508	257	348
All Hispanic	—	—	604	627	378	505	402	799	471	599	762	466	543
Non-Hispanic White	720	726	724	868	573	767	714	1058	694	959	1015	749	906
Non-Hispanic Black	399	439	392	343	505	408	362	451	639	516	480	592	489
18–24	452	479	303	367	351	381	358	392	363	411	400	404	394
25–29	175	228	183	231	193	202	193	255	190	214	209	201	196
30–34	183	206	211	222	206	227	230	227	211	233	209	228	240
35–39	155	158	235	235	204	238	188	236	219	226	225	214	200
40–44	174	196	221	256	206	266	204	266	213	264	229	203	215
45–49	157	178	230	253	202	231	192	256	202	229	226	188	208
50–54	155	162	214	224	236	224	196	227	235	222	247	201	211
55–59	107	121	186	167	169	216	196	173	181	211	208	174	204
60–64	0	0	0	0	0	0	0	262	237	243	236	238	233
65–69	0	0	0	0	0	0	0	167	144	193	186	164	177
Prevalence 18–59	46.8%	41.4%	41.0%	42.8%	39.6%	39.9%	45.2%	3.7%	3.2%	3.2%	10.7%	11.4%	11.2%
Age-adjusted prevalence	46.7%	41.5%	41.3%	43.1%	39.7%	39.9%	45.3%	3.7%	3.2%	3.1%	10.7%	11.4%	11.2%
Prevalence 18–69	—	—	—	—	—	—	—	3.7%	3.1%	3.4%	11.0%	11.9%	11.1%

Table 3:
HPV prevalence by site and genotype group and relative risk by vaccination status.

Prevalence of HPV in the U.S. is given for men and women ages 18–24 at genital and oral sites for all, oncogenic (Group 1 genotypes), and vaccine genotypes, stratified by vaccination status. People with at least one dose of vaccine were considered vaccinated. Here, %+ denotes the weighted HPV prevalence of the listed genotypes among the N people in the population. Prevalence entries with more than 30% relative standard error are marked * by and should be treated with additional caution. P-values for a comparison of proportions test ($\tilde{p}_{vac} < \tilde{p}_{un}$) are also given; bold p-values are significant at the $\alpha=0.05$ level of significance.

Group	Genotypes	Unvaccinated			Vaccinated			Relative risk		p-value
		N	%+	S.E.	N	%+	S.E.	RR	95% CI	
Genital, women 2009–2014	All	635	55.1	2.6	412	57.2	3.3	1.0	0.9–1.2	0.69
	Group 1	635	35.5	2.7	412	30.9	3.3	0.9	0.7–1.1	0.14
	6, 11, 16, 18	635	14.7	2.0	412	2.3	0.6	0.2	0.1–0.3	<0.01
Genital, men 2013–2014	All	252	34.9	3.3	52	32.6	5.6	0.9	0.6–1.4	0.36
	Group 1	252	20.2	2.8	52	15.4	3.1	0.8	0.5–1.2	0.12
	6, 11, 16, 18	252	3.4*	1.3	52	2.3*	2.3	0.7	0.1–5.4	0.34
Oral, women 2009–2014	All	679	4.5	1.1	430	4.0	1.1	1.0	0.4–1.8	0.36
	Group 1	679	1.8*	0.7	430	0.7*	0.3	0.4	0.1–1.2	0.06
	6, 11, 16, 18	679	1.0*	0.5	430	0.1*	0.2	0.1	0.0–1.3	0.05
Oral, men 2009–2014	All	603	6.3	1.4	90	8.3	2.6	1.3	0.6–2.8	0.75
	Group 1	603	3.3	1.0	90	5.1*	2.2	1.5	0.6–4.3	0.78
	6, 11, 16, 18	603	1.0*	0.5	90	0.0	0.0	—	—	0.02